Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions tied to its herpes simplex virus type 2 program, expansion of its hepatitis delta candidate into cholestatic liver diseases and expected clinical data readouts in 2027 and 2028.
Jason, an Assembly representative identified by the moderator, described the South San Francisco-based biotechnology company as focused primarily on recurrent genital herpes caused by HSV-2 and hepatitis delta, with a recent expansion into primary biliary cholangitis, or PBC, and primary sclerosing cholangitis, or PSC. He said the company historically has been virology-focused and is now broadening into liver disease, drawing on the experience of team members who previously worked in antiviral and liver disease programs, including at Gilead Sciences.
